Androgen Deprivation Therapy News and Research

RSS

Prostate cancer biology helps identify hormone therapy candidates

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

27 Sep 2026

$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

27 Sep 2026

Routine referral of prostate cancer patients to a cardiovascular specialist fails to cut cardiac events

Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy.

31 Aug 2026

Early radionuclide therapy delays progression in metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

6 Aug 2026

Breast and prostate cancer survival worsens with metabolic syndrome

A SEER-Medicare analysis of more than 200,000 adults aged 66 and older found that metabolic syndrome was associated with about twice the adjusted hazard of death from any cause after breast or prostate cancer. The condition was also linked to higher cancer-specific, cardiovascular-specific, and liver-failure-specific mortality, although the observational design prevents causal conclusions.

14 Jul 2026

Scientists identify new therapeutic target for deadly prostate cancer

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

28 May 2026

Scientists map genetic variants behind prostate cancer therapy failure

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research Fellow at Zhejiang Provincial People's Hospital, published a review entitled "Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer".

22 May 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

Oxybutynin shows promise in managing hot flashes for prostate cancer patients

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

2 Feb 2026

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

Metabolic reprogramming drives prostate cancer progression and treatment resistance

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy (ADT), the disease often progresses to castration-resistant prostate cancer (CRPC).

24 Jan 2026

Shorter hormone therapy may be enough for many men with prostate cancer

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first 9 to 12 months.

25 Nov 2025

Age impacts systemic therapy outcomes in metastatic prostate cancer

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age.

10 Nov 2025

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.

29 Sep 2025

Genomic testing speeds patient accrual in high-risk prostate cancer trial

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial's anticipated accrual completion date.

19 Sep 2025

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States.

1 Sep 2025

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.

28 Aug 2025

Starfish compound overcomes drug resistance in prostate cancer models

Researchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate cancer cells in vitro by bypassing common resistance pathways. CuC1 showed synergy with existing chemotherapies, though with only moderate selectivity for cancer cells.

5 Aug 2025